Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs iShares MSCI India ETF (INDA) Price & Performance

Amylx Pharmaceuticals IncTrade
iShares MSCI India ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs iShares MSCI India ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $24.03 (market cap $2.64B), while iShares MSCI India ETF trades at $49.92. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.

AMLXINDA
Market Cap
$2.64B
Sector
HealthBroad Market / Factor
52-Week High
$24.19$55.29
52-Week Low
$7.82$45.42
Enterprise Value
$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

iShares MSCI India ETF

INDA trades at $50.04, down 0.2% with a bullish technical signal from moving averages. The ETF reflects India's economic growth at 7.8% (CNBC, 2026-06-05) but faces headwinds from foreign outflows and sector-specific challenges in pharma and IT. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX indicates strong trend strength.

Outlook remains cautiously optimistic given India's strong economic fundamentals, though near-term risks include geopolitical tensions, monsoon uncertainties, and foreign capital rotation away from emerging markets. The ETF offers exposure to the world's fastest-growing large economy but requires monitoring of external pressures.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About iShares MSCI India ETF

INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.

Read more on INDA